Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q4 2015 call → NOWe need to determine if management conveys that the company's current business is visibly outgrowing its own size, i.e., that what is happening now is disproportionately large relative to the company's smallness. The transcript is about ALLETE, a utility holding company. They discuss various segments: regulated operations (Minnesota Power), ALLETE Clean Energy (wind), U.S. Water Services, and ALLETE Properties. They mention growth, acquisitions, projects like Great Northern Transmission Line, solar installation, etc. But do they convey that the company is small and that current activity is disproportionately large? They talk about growth, but not necessarily in terms of disproportion. They mention that ALLETE Clean Energy acquired wind facilities, but they don't say "we are small and this is huge relative to us." They talk about earnings guidance, cost control, etc. The question asks if management describes current activity, demand, or commitments arriving at a scale large relative to how small the company still is. I don't see explicit statements like "this single contract could double our size" or "we are a small company and this is massive." They mention that Essar could bring 110 MW of new load, but they say they don't anticipate sales in 2016. That's prospective. They mention PolyMet could bring 45-50 MW, but that's also pending permits. They talk about growth at ACE and U.S. Water, but not in a way that emphasizes disproportion. The company seems to be a mid-sized utility with multiple segments. They don't convey that they are small relative to what's happening. They talk about cost reductions, rate cases, etc. So the answer is likely NO. They don't express that the current business is outgrowing their size. They just report normal growth and opportunities. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.